Pre-procedural dual antiplatelet therapy in patients undergoing transcatheter aortic valve implantation increases risk of bleeding

Heart

Volumn 103, Issue 5, 2017, Pages 361-367

  Hioki, Hirofumi ^a   Watanabe, Yusuke ^a   Kozuma, Ken ^a   Nara, Yugo ^a   Kawashima, Hideyuki ^a   Kataoka, Akihisa ^a   Yamamoto, Masanori ^b   Takagi, Kensuke ^c   Araki, Motoharu ^d   Tada, Norio ^e   Shirai, Shinichi ^f   Yamanaka, Futoshi ^g   Hayashida, Kentaro ^h  

^a TEIKYO UNIVERSITY HOSPITAL   (Japan)

^b Toyohashi Heart Center Toyohashi   (Japan)

^c NEW TOKYO HOSPITAL   (Japan)

^d Eastern Yokohama Hospital   (Japan)

^e Sendai Kosei Hospital   (Japan)

^f KOKURA MEMORIAL HOSPITAL   (Japan)

^g SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

^h KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; ANTITHROMBOCYTIC AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DUAL ANTIPLATELET THERAPY; FEMALE; HEART INFARCTION; HOSPITALIZATION; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREOPERATIVE TREATMENT; PROSPECTIVE STUDY; PROSTHETIC VALVE THROMBOSIS; RISK ASSESSMENT; SINGLE ANTIPLATELET THERAPY; THROMBOSIS; TRANSCATHETER AORTIC VALVE IMPLANTATION; VERY ELDERLY; ADVERSE EFFECTS; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG ADMINISTRATION; JAPAN; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ODDS RATIO; POSTOPERATIVE HEMORRHAGE; REGISTER; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME;

AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INCIDENCE; JAPAN; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE HEMORRHAGE; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TRANSCATHETER AORTIC VALVE REPLACEMENT; TREATMENT OUTCOME;

EID: 84983479313     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2016-309735     Document Type: Article

References (24)

1. Mylotte D, Osnabrugge RL, Windecker S, et al. Transcatheter aortic valve replacement in Europe: adoption trends and factors influencing device utilization. J Am Coll Cardiol 2013;62:210-19.
2. Gilard M, Eltchaninoff H, Iung B, et al. Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med 2012;366:1705-15.
3. Makkar RR, Fontana GP, Jilaihawi H, et al. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med 2012;366:1696-704.
4. Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 2014;370:1790-8.
5. Thomas M, Schymik G, Walther T, et al. Thirty-day results of the SAPIEN aortic Bioprosthesis European Outcome (SOURCE) Registry: A European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 2010;122:62-9.
6. Webb JG, Pasupati S, Humphries K, et al. Percutaneous transarterial aortic valve replacement in selected high-risk patients with aortic stenosis. Circulation 2007;116:755-63.
7. Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol 2012;60:1438-54.
8. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989;129:125-37.
9. Amabile N, Azmoun A, Ghostine S, et al. Incidence, predictors and prognostic value of serious hemorrhagic complications following transcatheter aortic valve implantation. Int J Cardiol 2013;168:151-6.
10. Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012;366:1686-95.
11. Stabile E, Pucciarelli A, Cota L, et al. SAT-TAVI (Single Antiplatelet Therapy for TAVI) study: a pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. Int J Cardiol 2014;174:624-7.
12. Ussia GP, Scarabelli M, Mulè M, et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2011;108:1772-6.
13. Hassell ME, Hildick-Smith D, Durand E, et al. Antiplatelet therapy following transcatheter aortic valve implantation. Heart 2015;101:1118-25.
14. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-100.
15. Breet NJ, de Jong C, Bos WJ, et al. The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting. Thromb Haemost 2014;112:1174-81.
16. Watanabe Y, Kozuma K, Ishikawa S, et al. Hyper-response to clopidogrel in Japanese patients undergoing transcatheter aortic valve implantation. Int Heart J 2016;57:190-7.
17. Grube E, Laborde JC, Gerckens U, et al. Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study. Circulation 2006;114:1616-24.
18. Noble S, Asgar A, Cartier R, et al. Anatomo-pathological analysis after CoreValve Revalving system implantation. Eurointervention 2009;5:78-85.
19. Hein R, Abdel-Wahab M, Sievert H, et al. Outcome of patients after emergency conversion from transcatheter aortic valve implantation to surgery. Eurointervention 2013;9:446-51.
20. Berger JS, Frye CB, Harshaw Q, et al. Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. J Am Coll Cardiol 2008;52:1693-701.
21. Lip GY, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014;35:3155-79.
22. Magkoutis NA, Fradi S, Azmoun A, et al. Antiplatelet therapy in TAVI: current clinical practice and recommendations. Curr Pharm Des 2016;22:1888-95.
23. Vavuranakis M, Kolokathis AM, Vrachatis DA, et al. Atrial fibrillation during or after TAVI: incidence, implications and therapeutical considerations. Curr Pharm Des 2016;22:1896-903.
24. Di Mario C, Eltchaninoff H, Moat N, et al. The 2011-12 pilot European Sentinel Registry of Transcatheter Aortic Valve Implantation: in-hospital results in 4,571 patients. EuroIntervention 2013;8:1362-71.